Skip to main content
TYRA
NASDAQ Life Sciences

Tyra Biosciences Reports Q1 Results, Extends Cash Runway to H2 2028 with $147.9M ATM Proceeds

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$34.52
Mkt Cap
$2.074B
52W Low
$8.75
52W High
$40.65
52W Position info
295% above low
Off High info
15% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

TYRA has more than doubled off its 52-week low of $8.75.

Summary

Tyra Biosciences filed its Q1 2026 report, detailing an extended cash runway into the second half of 2028, supported by $147.9 million in net proceeds from its at-the-market offering program.


Key Events · Earnings and Guidance · TYRA

  • Cash Runway Extended

    The company's cash, cash equivalents, and marketable securities of $383.5 million as of March 31, 2026, are projected to fund operations into the second half of 2028, extending the previous guidance of 'at least 2027'.

  • ATM Offering Nearly Fully Utilized

    Tyra Biosciences raised $147.9 million in net proceeds during Q1 2026 by selling 4,690,532 shares through its $150 million at-the-market (ATM) offering program, which was established in May 2025.

  • Increased Operating Expenses

    Research and development expenses increased to $33.5 million in Q1 2026 from $25.0 million in Q1 2025, and general and administrative expenses rose to $8.5 million from $6.9 million, reflecting ongoing pipeline advancement.

  • Net Loss Widened

    The company reported a net loss of $39.3 million for Q1 2026, compared to a net loss of $28.1 million for the same period in 2025.


Analysis · TYRA · Life Sciences

This quarterly report provides the detailed financial results for Q1 2026, confirming the company's cash, cash equivalents, and marketable securities of $383.5 million are sufficient to fund operations into the second half of 2028. This extends the previously disclosed runway of 'through at least 2027' from the last 10-K. The improved liquidity is largely due to the utilization of its at-the-market (ATM) offering program, which generated $147.9 million in net proceeds during the quarter, nearly exhausting the $150 million program. While the company reported an increased net loss of $39.3 million and higher operating expenses, these reflect continued investment in its clinical pipeline. Several executives also adopted routine 10b5-1 trading plans during the quarter, which are pre-planned arrangements and not indicative of immediate insider selling.

How filings like this one have moved

In the 30 days to Nov 3, 2026, 32.3% of the 2077 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TYRA was trading at $34.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $8.75 to $40.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TYRA - Latest Insights

TYRA
Sep 17, 2026, 4:32 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $24.43
Real-time Price: $21.64 info
Change: -$2.79 (-11%) info
Market Cap: $1.467B info
TYRA
Sep 14, 2026, 7:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.20
Real-time Price: $21.64 info
Change: -$3.56 (-14%) info
Market Cap: $1.467B info
TYRA
Sep 14, 2026, 7:09 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $25.20
Real-time Price: $21.64 info
Change: -$3.56 (-14%) info
Market Cap: $1.467B info
TYRA
Sep 14, 2026, 6:45 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $21.70
Real-time Price: $21.64 info
Change: -$0.060 (-0.28%) info
Market Cap: $1.467B info
TYRA
Sep 14, 2026, 6:33 AM EDT
Filing Type: FWP
Importance Score:
7
Price at Filing: $21.70
Real-time Price: $21.64 info
Change: -$0.060 (-0.28%) info
Market Cap: $1.467B info